BACKGROUND AND PURPOSE: The brachytherapy dose algorithm of the American Association of Physicists in Medicine Task Group (TG) Report 43 overrides all tissue materials with water.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In reality, dose discrepancies will occur around tissue calcifications. This study investigates these perturbations in low dose rate prostate brachytherapy dosimetry.
MATERIALS AND METHODS: 43 cancer patients with prostatic calcifications are identified. Geant4 Monte Carlo (MC) simulations are made with materials assigned based on TG186 recommendations. Five dose calculation scenarios are presented: MC in water (MCW), MCW with calcifications, (MCCA), MCCA with seeds (MCCASEED) and full tissue definition and seeds with dose to medium in medium (FMC) and dose to water in medium (FMC-Dw,m).
RESULTS: The mean FMC prostate D90 (V100) difference relative to TG43 is -6.4% (range [-1.8, -14.1]) (-2.6% [-0.3, -6.7]). For MCCA we obtained -3.9% [-1.0, -8.7] (-1.5% [-0.2, -4.1]). The mean urethra D10 difference is -4.5% [-1.3, -9.9] for FMC, -2.4% [-0.7, -5.1] with MCCA. FMC-Dw,m D90 has a -0.45% smaller dose difference than FMC on average. The calcification/prostate volume ratio is a good predictor of dose perturbation (R2=0.75).
CONCLUSION: Based on these results, calcifications alter the dose coverage and may have severe dose perturbation that requires recalculation.
Collins Fekete CA, Plamondon M, Martin AG, Vigneault É, Verhaegen F, Beaulieu L. Are you the author?
Département de physique, de génie physique et d'optique et Centre de recherche sur le cancer, Université Laval, Québec, Canada; Département de radio-oncologie et CRCHU de Québec, CHU de Québec, Québec, Canada; Département de radio-oncologie et CRCHU de Québec, CHU de Québec, Québec, Canada; Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands; Medical Physics Unit, McGill University Health Centre and Department of Oncology, McGill University, Montréal, Québec, Canada. ; ; ; ; ;
Reference: Radiother Oncol. 2015 Feb 19. pii: S0167-8140(15)00075-4.